# NAD+ Research: Mechanism, Aging Biology and the Study Record | NAD+ > NAD+ research: the redox role, the NAD-consuming enzymes (sirtuins, PARPs, CD38), the age-related decline, and the preclinical findings — each claim cited to a study. A literature digest. The redox role, the enzymes that burn through the pool, the age-related decline, and the preclinical findings — pinned to source, sorted by how much weight each one can bear. ## In plain English NAD+ does two jobs in a cell. First, it is an energy go-between: it carries electrons through the chemistry that turns food into ATP (the cell's usable energy), flipping between a "loaded" form (NADH) and an "empty" form (NAD+) over and over (this electron-carrying chemistry is called redox). Second, it is a *consumable* — certain repair-and-maintenance enzymes use it up as they work, so the cell has to keep making more. As you age, the supply drops and one enzyme that destroys NAD+ (CD38) ramps up, leaving less to go around. That decline is the biology behind the whole "boost your NAD+" idea. Below is the mechanism and the study record, kept honest about which findings come from humans and which from mice. ## The redox engine and the enzymes that consume it NAD+ is the cell's central redox carrier. It shuttles electrons through glycolysis, the TCA cycle and mitochondrial oxidative phosphorylation — cycling NAD+ ⇄ NADH — to drive ATP synthesis [5]. That redox role is ancient and non-negotiable; without it, energy metabolism stops. Layered on top is a second economy: NAD+ is *consumed* (not just recycled) by three enzyme families. Sirtuins (SIRT1–SIRT7, NAD+-dependent deacylases) regulate metabolism, stress resistance and DNA repair. PARP1 (poly(ADP-ribose) polymerase 1) consumes large amounts of NAD+ to repair DNA damage. And CD38 / CD157 are NAD-consuming ectoenzymes that rise with age and inflammation [5]. Because all three draw on the same NAD+ pool, they compete — and a foundational review framed restoring NAD+ as a candidate strategy against age-related disease precisely because that pool shrinks with age [5]. ## Why NAD+ falls with age — the CD38 story The clearest mechanistic account of age-related NAD+ decline points at CD38. In mice, CD38 is the principal NAD+-consuming enzyme, and its activity rises with age, driving the fall in tissue NAD+ [2]. CD38-knockout mice are protected: deleting CD38 preserves NAD+ levels and SIRT3 activity and improves mitochondrial function and metabolic health with age [2]. This is the rationale behind precursor supplementation — if an aging cell is losing NAD+ partly because CD38 is eating it, topping up the supply with NMN or NR is one way to defend the pool. Worth flagging plainly: this is **mouse** work. It explains *why* you might boost NAD+; it does not by itself prove that doing so extends human healthspan. ## How precursors rebuild the pool The body makes NAD+ by three routes: de novo from the amino acid tryptophan, the Preiss-Handler pathway from nicotinic acid (niacin), and — dominant in mammals — the salvage pathway, which recycles nicotinamide back into NAD+ via the rate-limiting enzyme NAMPT [5]. Oral precursors plug into this machinery. NR is converted to NMN by NRK kinases and then to NAD+, taking a route independent of Preiss-Handler [5]. The plumbing is more tangled than it looks: isotope tracing in mice showed circulating host nicotinamide feeds the gut microbiome, which converts it to nicotinic acid used for host NAD+ synthesis, and that oral NR reaches host NAD+ partly via microbial conversion [12]. NAMPT also follows a circadian rhythm and is induced by exercise [5] — context for the timing questions below. ## What the preclinical record shows beyond metabolism Outside core metabolism, animal studies have probed NAD+ in specific tissues — and these are explicitly preclinical. In mice, photoreceptor-specific deletion of the NAD+ enzyme Nampt caused retinal degeneration that NMN could rescue, identifying NAD+ biosynthesis as essential for vision and a shared target across blinding diseases [11]. In a noise-exposure model, NR given before exposure preserved cochlear hair-cell ribbon synapses and aided hearing recovery [14]. And a review of human and laboratory evidence reports that nicotinamide replenishes the cellular NAD+ pool and, applied topically, reduced progression of skin aging and hyperpigmentation in clinical trials while being well tolerated [13]. These widen the mechanistic map; they are mostly rodent or topical findings, and the cautions on [the safety page](/nad-safety) about extrapolating from mice to people apply throughout. ## Does NAD cause weight gain? The dealt studies do not show NAD+ precursors causing weight gain. Human trials report no body-composition change with NMN — for example 250 mg/day for 10 weeks improved muscle insulin sensitivity but did not alter body composition or HbA1c [1]. Body weight was not an outcome these trials moved in either direction. ## Does NAD help with weight loss? Some trials report improved muscle insulin sensitivity at NMN doses around 250 mg/day [1], but the dealt studies do not establish weight loss as an outcome and report no body-composition change. NAD+ precursors are not demonstrated weight-loss agents in this evidence base. ## Does NAD make you look younger? No trial in the dealt evidence demonstrates a cosmetic "younger" effect. Mechanistic reviews link declining tissue NAD+ to aging biology — sirtuins, PARPs, CD38 [5] — and topical nicotinamide has reduced skin-aging signs in clinical trials [13], but systemic human anti-aging outcomes remain preliminary [15]. ## Does NAD help with fertility? Fertility is outside the dealt evidence base. Reviews caution that most of the strongest NAD+ data are mechanistic or rodent, and that human clinical endpoints remain unproven [15]. The studies summarized here did not measure fertility outcomes. ## What is the best time to take NAD, morning or night? No trial establishes a best time of day to take a precursor. NAMPT, the salvage-pathway enzyme, and NAD+ itself follow a circadian rhythm [5], which is sometimes cited in timing discussions, but the dealt randomized trials dosed on fixed schedules without comparing morning versus night, so the evidence does not pick a winner. --- The NAD+ hype screenshotted and stapled to its source — the precursor trials that genuinely raised blood NAD+ stamped confirmed, the hard-outcome claims stamped preliminary, oral precursors kept apart from the compounded IV NAD+ behind a Class I recall, and the contested NMN status read as a dispute, not a ban; no clinic behind this corkboard and nothing here dosed, infused, prescribed, or sold.